The (R)- isomer of isometheptene decreases trigeminal sensitivity in a rat model of primary headache
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Introduc.on	
  

Using behavior methods of monitoring trigeminal allodynia in rats, our group discovered a rat
with spontaneous episodic trigeminal allodynia (STA) (Oshinsky et al, 2012). The model was
established through 18 generations of inbreeding for testing analgesics and the further
understanding of mechanisms of migraine. STA rats experience similar symptoms to human
migraine patients, such as episodic trigeminal sensitivity, phonophobia, responsiveness to
abortive and prophylactic headache treatments, and sensitivity to migraine triggers. A second
well-characterized model of repeated dural inflammatory stimulation (IS), in which an
inflammatory stimulant is infused over the dura, also results in persistent headache behavior
that has been accepted as a valid model for drug testing.
Although the pathological
mechanisms between the two models are different, one being considered idiopathic or a
spontaneous model and the other inflammatory in nature, the precise mechanism(s) remain
elusive.
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Experiments using electrical and mechanical stimulation of the dura in animals with no history
of head pain have been used to elucidate the mechanisms of the trigeminovascular system at
the level of the trigeminal ganglion, trigeminal nucleus caudalis, periaqueductal gray, and the
thalamus. The limitation of these acute models is that electrical and mechanical stimulation of
the dural blood vessels does not cause long lasting pain similar to recurrent headache pain in
humans. Two animal models for the investigation of headache pathophysiology that include
aspects of the chronic nature of headache were included in this study. These models provide a
new approach to study the pathophysiology of recurrent headache and support validation of
novel treatments.
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Isometheptene is thought to be the active ingredient of the commonly known headache
medication, Midrin. Previously, we found only the (R) enantiomer to be effective in alleviating
headache behavior in two models of headache compared to the (S) enantiomer.
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Figure 1: R-isomer of the isometheptene (ISO) dose response in the STA Model. STA rats showed a
significant increase in trigeminal threshold in the 1 mg/kg of ISO treatment at the 0.5 hr (**P<0.01), 1.5 hr
(*P<0.05), and 2.5 hr (*P<0.05). Testing of 10 mg/kg of ISO showed increases in thresholds at 1.5 hr
(**P<0.01) and 2.5 hr (***P<0.001). Testing of 30 mg/kg of ISO showed increases in trigeminal thresholds
atAthe 0.5 hr (***P<0.001), 1.5 hr
B (**P<0.01), 2.5 hr (***P<0.001),
C 3.5 hr (**P<0.01), and 24 hr (***P<0.001).
Testing of 60 mg/kg of ISO showed increases in trigeminal thresholds at the 1.5 hr (*P<0.05), 2.5
D hr
(****P<0.001), and 3.5 hr (**P<0.001).

Figure 2: R-isomer of the isometheptene (ISO) dose response in the IS Model. Treatment with 10 mg/kg of ISO
showed increases in trigeminal thresholds at the 1.5 hr (****P<0.0001) and 2.5 hr (****P<0.0001). Administration of 30 mg/
kg of ISO resulted in increases in trigeminal thresholds at the 1.5 hr (*P<0.05) and 2.5 hr (**P<0.01). Testing of 60 mg/kg
of ISO showed increases in trigeminal thresholds at the 1.5 hr (***P<0.001), 2.5 hr (****P<0.0001) and 24 hr (***P<0.001).

The aim of this study is to determine the dose response of the (R)-isomer of isometheptene on
trigeminal sensitivity in the STA and IS rat models and study the mechanism of action of
isometheptene.

Methods	
  
Experimental Design
To determine the efficacy of the R-isomer of isometheptene in the two rat trigeminal headache
models, a 4 point dose response curve was conducted.
Periorbital thresholds, measured using von Frey filaments, were obtained to determine
trigeminal sensitivity prior to and at 0.5 hr-, 1.5 hr-, 2.5 hr-, 3.5 hr-, and 24 hr-post-treatment
with either (R)-isometheptene (1, 10, 30, 60 mg/kg), or saline vehicle. A 100 mg/kg dose was
omitted due to mucate salt related fatalities observed in the rat models, though it was well
tolerated in human testing. All treatments were administered intraperitoneally. Von Frey data
was analyzed using Prism, and a Two-Way ANOVA was performed to determine statistical
significance with the factors group and time.

Figure 3: Trigeminal ganglia nNOS immunostaining. Green staining indicates nNOS, blue represents
DAPI staining. V1 ophthalmic branch was selected for imaging. A. IS model saline control. B. IS model RISO 60mg/kg dose. C. STA model saline treatment. D. STA model 60 mg/kg testing. Animals were perfused
immediately following 24 hr. VF time point. Statistical significance of positively stained nNOS cells was
determined by cell counting (**P<0.004) n=4

§ Treatment with (R)-isometheptene showed better efficacy for the IS model at a lower dose
compared to the STA model.
§ Treatment with (R)-isometheptene in the STA model resulted in a significant improvement in
trigeminal thresholds that persisted for 24 hours.
§ Side effects at the 60 mg/kg dose included seizures in a subset of animals, possibly affecting the
thresholds in this treatment group for both models.
§ Treatment with (R)-isometheptene reduced the number of nNOS and CGRP positive trigeminal
ganglia neurons and slightly reduced CGRP immunoreactivity in the TNC for both STA and IS
models.

Model Generation

The IS animals were surgically generated through cranial cannula implantation. This allowed
for repeated dura stimulation that leads to sensitization of the trigeminovascular afferents and
secondary order neurons in the brainstem (Oshinsky et al, 2007). The rats received up to 15
infusions of prostaglandin onto the dura in order to transition to a lower trigeminal von Fry
threshold. Following the completion of infusions, the animals undergo one week with no
behavior testing or infusions, followed by a week of behavior testing to determine if the animal
is chronically sensitive.

Discussion	
  &	
  Conclusions	
  
§ Findings show differential dose-response effects of (R)-isometheptene treatment on trigeminal
sensitivity that are dependent on the headache model.

Following the completion of the 24 hr-post treatment time point, animals were perfused with
4% PFA. Trigeminal ganglion and brainstem were collected and sectioned at 20µm.
Subsequently, immunostaining was performed to assess the changes in levels of two
nociceptive signaling molecules, calcitonin gene-related peptide (CGRP) and neuronal nitric
oxide synthase (nNOS). Standard immunofluorescence protocols used previously were
followed for the staining of CGRP and nNOS (Diautolo et al, 2016) .

The STA animals selected for this study represented the 17-20th generation of inbreeding and
exhibited the spontaneous trigeminal allodynia trait. Animals were trained to enter restraint
freely in order to perform von Frey and establish periorbital baseline.

Figure 4: Trigeminal ganglia CGRP immunostaining. Green staining indicates CGRP, blue represents DAPI staining. V1
ophthalmic branch was selected for imaging. V1 ophthalmic branch was selected for imaging. A. IS model saline treatment.
B. IS model R-ISO 60mg/kg dosage. C. STA model saline administration. D. STA model 60 mg/kg testing. Animals were
perfused immediately following 24 hr. VF time point. Statistical significance of positively stained CGRP cells was determined
by cell counting (*P<0.016) n=4

§ Findings supports the (R)-isomer of isometheptene as a therapeutic for chronic spontaneous type
headaches such as migraine, as well as for inflammatory pain conditions.
Figure 5: TNC nNOS immunostaining. V1 region
was selected for imaging. A. IS model saline
control. B. IS model R-ISO 60mg/kg dose. C. STA
model saline treatment. D. STA model 60 mg/kg
testing. Examples of nNOS positive cells are
indicated by arrows.

Figure 6: TNC CGRP immunostaining. V1 region
was selected for imaging. A. IS model saline
control. B. IS model R-ISO 60mg/kg dose. C. STA
model saline treatment. D. STA model 60 mg/kg
testing.
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